AstraZeneca has presented new data from its pipeline of investigational cancer medicines at the European Society of Medical Oncology (ESMO) 2014 Congress in Madrid. Together with MedImmune, its global biologics research and development arm, the company presented data from over 40 abstracts, building on results highlighted earlier this year at the American Society for Clinical Oncology (ASCO) congress. Highlights include: · Preliminary results in the ongoing Phase I MEDI4736 (PD-L1) + tremelimumab (CTLA-4) combination study in patients with non-small cell lung cancer (NSCLC) who have already received prior cancer treatments. · Updated data from a Phase I monotherapy study of MEDI4736 in patients with metastatic squamous cell carcinoma of the head and neck (SCCHN). · Further data from the Phase I/II study of AZD9291 in patients with epidermal growth factor receptor mutation positive (EGFRm) T790M+ advanced NSCLC who had disease progression following treatment with an EGFR tyrosine kinase inhibitor (TKI). Briggs Morrison, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca said: "At ASCO we presented data demonstrating the strength and rapid progression of our oncology pipeline, which we believe has the potential to redefine the way cancer patients are treated. The data presented here at the ESMO 2014 Congress further builds our clinical understanding of the key assets across our core areas of focus: immuno-oncology, the genetic drivers of cancer and acquired resistance and DNA damage repair. We are encouraged by the results we are seeing and look forward to providing further updates as we continue to work at pace to get these potentially life -changing medicines to patients." Immuno-oncology MedImmune presented updates on its novel immunotherapy portfolio at the ESMO 2014 Congress through eight abstracts, which reinforce the clinical activity and tolerability of MEDI4736 as monotherapy and highlight the potential of the combination of MEDI4736 and tremelimumab. Specifically, preliminary data was presented on Saturday, 27 September from the ongoing Phase I study of MEDI4736 in combination with tremelimumab in NSCLC patients who have already received prior cancer treatments (Antonia, abstract #1327P). The data covered anti-tumour activity and the tolerability profile of the combination. "We are pleased with the results from MEDI4736 in combination with tremelimumab," said Edward Bradley, Senior Vice President, R&D and Oncology iMED Head, MedImmune. "While it is still early with a limited data set, the tolerability profile is encouraging. We have also seen some evidence of clinical activity in patients who have failed prior lines of therapy and whose tumour does not express PD-L1. This supports our strategy to explore this combination more broadly, particularly in the PD-L1 negative population. This trial will identify the optimal dose to take into our Phase III clinical programme." MEDI4736 is an investigational, engineered, human monoclonal antibody directed against an immune system 'checkpoint', known as programmed cell death ligand 1 (PD-L1). Tremelimumab targets a separate immune checkpoint, CTLA-4. Several checkpoints such as PD-L1 and CTLA-4, which the body normally uses to dampen the immune response, can be hijacked by tumour cells to escape detection by the immune system and facilitate malignant growth. Immunotherapies are designed to enable the immune system to counteract these tactics employed by cancer cells. By targeting more than one hijacked checkpoint, combination therapies have the potential to be more effective than monotherapy in treating this disease. MedImmune has initiated additional Phase I immunotherapy combination trials, including MEDI4736 + MEDI0680 (PD-1) and MEDI4736 + MEDI6469 (OX40)*. Ongoing Phase I data were also presented on Saturday, 27 September, assessing the clinical activity and safety profile of MEDI4736 as a monotherapy in patients with NSCLC (Antonia, abstract #1325P). On Sunday, 28 September, MedImmune presented additional MEDI4736 monotherapy data in a Phase I dose -expansion study of patients with solid tumours. This data set provided further information on the clinical activity and tolerability profile of MEDI4736 across a range of solid tumours, including pancreatic cancer, gastric cancer and hepatocellular cancer (Segal, abstract #1058PD). A separate analysis of patients with metastatic SCCHN was also shared (Fury, abstract #988PD). The Phase I data, coupled with the pre-clinical data, support the accelerated development of MEDI4736 into Phase III clinical trials in both NSCLC and SCCHN. Separately, MedImmune has also recently commenced a Phase I human OX40 agonist (MEDI6383) monotherapy study in cancer patients with recurrent or metastatic solid tumors. Small molecules On Sunday, 28 September, AstraZeneca presented updates on key assets in its small molecule portfolio, including the investigational NSCLC medicine AZD9291, a highly selective, irreversible inhibitor of both the activating sensitising EGFR mutation (EGFRm) and the resistance mutation T790M, IRESSA® (gefitinib) and the PARP inhibitor olaparib. Updated data from the ongoing AURA Phase I/II study (Yang, Abstract #449PD) provided an update on the activity and safety of AZD9291 in patients with EGFRm T790M+ advanced NSCLC whose disease had progressed following treatment with an EGFR TKI. This builds on data from the AURA study presented earlier in the year at ASCO. AstraZeneca has initiated both Phase II and Phase III studies in this patient population (AURA 2 and AURA 3 respectively). In addition, a Phase III study evaluating AZD9291 in first line EGFRm advanced NSCLC is scheduled to start later this year. AstraZeneca is also currently investigating combinations of AZD9291 with MEDI4736, and with other investigational drugs selumetinib (small molecule MEK inhibitor) and AZD6094 (small molecule MET inhibitor) in NSCLC. Antoine Yver, Head of Oncology, Global Medicines Development, AstraZeneca, said "The updated data we have presented at the ESMO 2014 Congress reinforce our strategy of moving rapidly into Phase III development with AZD9291 in EGFRm T790M+ advanced non-small cell lung cancer. We have already made significant progress with our accelerated development programme and we anticipate filing for regulatory approval in the US in the second half of 2015." AstraZeneca also presented data from the Phase III IMPRESS study for IRESSA, a second line, combination study in patients with EGFRm advanced NSCLC who have acquired resistance to first line IRESSA. Separately, new data was presented on the impact of olaparib on the quality of life of patients with BRCA mutated platinum-sensitive relapsed ovarian cancer. The Committee for Medicinal Products for Human Use is expected to provide its opinion on olaparib in the EU on 23 October 2014, and the US FDA Prescription Drug User Fee Act date is set for 3 January 2015. AstraZeneca hosted a briefing for analysts and investors at the ESMO 2014 Congress on the evening of Sunday, 28 September 2014. The presentation from the event is available at: astrazeneca.com/investors (http://www.astrazeneca.com/investors). *MEDI6469 is an in-licensed asset from Agonox. About MedImmune MedImmune is the global biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca's three global R&D centers. For more information, please visit www.medimmune.com. About AstraZeneca AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com CONTACTS Media Enquiries Esra Erkal-Paler +44 20 7604 8030 (UK/Global) Vanessa Rhodes +44 20 7604 8037 (UK/Global) Ayesha Bharmal +44 20 7604 8034 (UK/Global) Jacob Lund +46 8 553 260 20 (Sweden) Michele Meixell + 1 302 885 6351 (US) Investor Enquiries Karl Hard +44 20 7604 8123 mob: +44 7789 654364 Jens Lindberg mob: +44 7557 319729 Anthony Brown +44 20 7604 8067 mob: +44 7585 404943 Eugenia Litz +44 20 7604 8233 mob: +44 7884 735627 29 September 2014 -ENDS-
ASTRAZENECA UPDATES ON PROGRESS OF ONCOLOGY PIPELINE AT
Top 10 Most Recent News Articles
Kansai Powers Up US Grid with Bold Investment Move
Betting Big on Battery Storage Let's unpack this big move by Kansai Electric. Anytime a major player like Kansai steps out of its home turf, folks better pay attention. Looks like Kansai's gotten cozy with Elevate and ArcLight, nabbing a minority stake in Prospect Power. This ain't your average widget factory—it's a beefy 150MW/600MWh battery energy storage facility in...
Continue Reading
RBC Grabs Top Honors for Sustainable Investing Leadership
A New Feather in RBC's Cap RBC Wealth Management has racked up more accolades, crowned as the Best Private Bank in Canada and celebrated for its prowess in impact and sustainable investing on the global stage. These distinctions flew in courtesy of the PWM Global Private Banking Awards—a heavyweight recognition in the wealth management world. Award Winning Strategy in...
Continue Reading
Radiate Holdco's Q3 Results: What We Know Now
Digging Into Third Quarter Highlights Radiate Holdco, LLC has just thrown its third-quarter financial hat into the ring, stirring up some interest in the world of FLFO secured notes and senior notes. The folks in Princeton, N.J., sure know how to keep things exclusive—this intel is only for those holding their Notes or in the pretty exclusive club of qualified...
Continue Reading
Kinross Gold Faces Class Action Over Misleading Forecasts
A Golden Opportunity Gone Wrong Well, it looks like Kinross Gold Corporation (NYSE: KGC) has stuck its foot in it again. This time, they're in hot water over claims that don't exactly hold up under scrutiny. If you're holding KGC, you've probably heard about the fresh class action lawsuit alleging they misled investors about their production targets. Naturally, the...
Continue Reading
SKE Capitalizes on Halloween Events in London
SKE's Bold Step into London's Halloween Vibe Hah! Who would've thought that vaping and Halloween could be a match made in heaven? This year, SKE threw its hat into the ring and wrestled for attention in London’s bustling Halloween music scene. Imagine an entire warehouse pulsing not just with beat-heavy electronic music, but the energy of vaping enthusiasts courtesy of...
Continue Reading
Sabre Unveils AI Travel Tech: A Bold New Frontier
Sabre's Game-Changing AI Travel Integration I'm no stranger to bold moves in the travel industry, but what Sabre's rolling out tomorrow might just be the biggest leap we've seen in a while. They're unleashing what's called the first global travel plug-in within Grok Bot, marking a significant shake-up in the travel tech sphere. Too many tech upgrades in this business...
Continue Reading
Elah Holdings' Q3 2026 Report Sparks Investor Interest
Elah Holdings Drops Their Q3 2026 Numbers Eat your heart out, folks—Elah Holdings has just dropped their third quarter report for 2026, and it caught some eyes. This ain't your run-of-the-mill, brush-right-past-it release. They're out there, waving their flag high in the competitive marketplace, trying to tell us they mean business. If you missed the announcement, they...
Continue Reading
Loyalty Programs Cut $1500 Annually for Consumers
Loyalty Programs: An Essential Tool for Households In a world where every dollar counts, retail loyalty programs have become more than just a marketing strategy—they're lifelines for American households scraping through each month. According to fresh research by the Retail Industry Leaders Association (RILA) and conducted by market research leader Circana, these...
Continue Reading
Hermes AI: A New Era in Market Analysis?
Revolution or Just Another App? In a world where stock market insights are as cryptic as hieroglyphs to the average Joe, here comes the Hermes AI Analyzer, breaking onto the scene and promising to translate Wall Street's complex lingo into plain, simple language. It's the brainchild of Turkish engineer Umut Tugrul, who has spent decades in the trenches of software...
Continue Reading
equipifi's BNPL Shop: New Ammo for Credit Unions
equipifi's 'Shop': The Big Play in Banking Look, here’s the deal—equipifi just lobbed a new grenade into the finance battlefield, arming credit unions and community banks with 'Shop', their own Buy Now, Pay Later (BNPL) platform. The goal? To put them toe-to-toe with the big fintech wolves—something these smaller guys desperately needed. It's a meaty move, no...
Continue ReadingTop 5 Most Recently Viewed Articles
Radiant Striping's Community Commitment through Service Initiatives
Radiant Striping's Charitable Impact on the Community Radiant Striping, a veteran-owned company, is making waves in their community through generous donations of parking lot striping and other services to local organizations. It's not just about the perfect paint job; it’s about building safer, more welcoming spaces for families and visitors alike. A Mission Rooted in...
Continue Reading
Supernus Pharmaceuticals Announces Participation in Key Healthcare Event
Supernus Pharmaceuticals' Participation in the Healthcare Conference Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a dedicated biopharmaceutical company, is excited to announce its upcoming participation in a significant healthcare conference. The conference will take place soon, and prominent figures from the company, including Jack Khattar, President and CEO, are set...
Continue Reading
CTC Celebrated as Top Veteran-Friendly Employer in 2024
Concurrent Technologies Corporation Recognized in 2024 Concurrent Technologies Corporation (CTC) is thrilled to announce its inclusion in the U.S. Veterans Magazine’s Top Veteran-Friendly Employers list for 2024. This achievement marks the fourth consecutive year that CTC has received this important recognition. How U.S. Veterans Magazine Evaluates Employers Each year,...
Continue Reading
Chimerix Announces Inducement Grant of Stock Options
Chimerix Announces Inducement Grant of Stock Options Chimerix (NASDAQ:CMRX), a prominent biopharmaceutical company, has announced a notable inducement award for a newly hired employee. This grant includes non-statutory stock options totaling 150,000 shares of the company's common stock, underscoring Chimerix's dedication to attracting top talent in the competitive biotech...
Continue Reading
EarFun Showcases Cutting-Edge Wireless Audio Innovations
Discover the Latest Innovations from EarFun at CES 2025 EarFun, a prominent name in wireless audio technology, is set to unveil a range of cutting-edge products that will redefine the audio experience. Their participation in CES 2025 promises to highlight significant advancements that cater to diverse listening needs. Innovative AI-Powered Features The spotlight will be...
Continue Reading